| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-08 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-06 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.16 | 7e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.004 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |